

# Future trends in photodynamic therapy: Innovations in light-based medicine.

Haojie Wu\*

Division of Obstetrics and Gynecology, Peking University Third Hospital, China

\*Correspondence to: Haojie Wu, Division of Obstetrics and Gynecology, Peking University Third Hospital, China. E-mail: haowu@yahoo.com

*Received: 03-Sep-2025, Manuscript No. AADRSC-25-167970; Editor assigned: 04-Sep-2025, PreQC No. AADRSC-25-167970(PQ); Reviewed: 17-Sep-2025, QC No. AADRSC-25-167970; Revised: 22-Sep-2025, Manuscript No. AADRSC-25-167970(R); Published: 27-Sep-2025, DOI:10.35841/aadrsc-9.3.267*

## Introduction

Photodynamic therapy (PDT) has emerged as a minimally invasive and highly targeted therapeutic modality, utilizing the synergistic action of a photosensitizing agent, light of a specific wavelength, and molecular oxygen to generate reactive oxygen species (ROS) that induce cell death. It is used in various medical fields, including dermatology, oncology, and ophthalmology. While traditional PDT has proven effective, ongoing research and technological developments are set to transform this light-based treatment. From next-generation photosensitizers to image-guided therapy and combination approaches, the future of PDT is rich with promise. This article explores the major innovations shaping the next era of photodynamic therapy. [1].

A major area of innovation lies in the development of improved photosensitizers. Traditional agents like porfimer sodium and 5-aminolevulinic acid (ALA) have limitations, including prolonged photosensitivity, low selectivity, and poor tissue penetration. Examples include chlorin-based compounds (e.g., temoporfin), bacteriochlorins, and phthalocyanines, which are now being evaluated in clinical trials. [2].

A major area of innovation lies in the development of improved photosensitizers. Traditional agents like porfimer sodium and 5-aminolevulinic acid (ALA) have limitations, including prolonged photosensitivity, low selectivity, and poor tissue penetration. Examples include chlorin-based compounds (e.g., temoporfin), bacteriochlorins, and phthalocyanines, which are now being evaluated in clinical trials [3].

A major area of innovation lies in the development of improved photosensitizers. Traditional agents

like porfimer sodium and 5-aminolevulinic acid (ALA) have limitations, including prolonged photosensitivity, low selectivity, and poor tissue penetration. Examples include chlorin-based compounds (e.g., temoporfin), bacteriochlorins, and phthalocyanines, which are now being evaluated in clinical trials. This image-guided approach enhances accuracy and allows clinicians to adapt treatment parameters during procedures. [4].

Recent research has revealed PDT's ability to stimulate an immune response. ROS production can induce immunogenic cell death (ICD), releasing tumor-associated antigens and danger signals. This has led to the concept of photoimmunotherapy, where PDT is combined with immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) to boost systemic anti-tumor immunity [6]. Such combinations are being tested in preclinical models with promising results, especially in cancers resistant to traditional therapies. [5].

## Conclusion

The future of photodynamic therapy is bright and dynamic. Innovations in photosensitizers, light delivery, targeting mechanisms, and therapeutic combinations are pushing the boundaries of what PDT can achieve. As it evolves into a more precise, deeper-acting, and immunologically active treatment, PDT is likely to become an integral part of mainstream therapeutic regimens for both oncological and non-oncological conditions. With the integration of nanotechnology, AI, and personalized medicine, photodynamic therapy is not just a light-based treatment—it is a light-guided revolution in medicine.

## References

1. Gilmore SJ. Control strategies for endemic childhood scabies. *PloS One*. 2011;6(1):e15990.
2. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. *New England J Med*. 2010;362(8):717–25.
3. Mellanby K. The development of symptoms, parasitic infection and immunity in human scabies. *Parasitol*. 1944;35(4):197–206.
4. Dairkee SH, Mayall BH, Smith HS, et al. Monoclonal marker that predicts early recurrence of breast cancer. *Lancet*. 1987;(8531):514.
5. Diaz LK, Cryns VL, Symmans WF, et al. Triple negative breast carcinoma and the basal phenotype: From expression profiling to clinical practice. *Adv Anat Pathol*. 2007;14(6):419–30.